A potential novel therapeutic target for invasive soft tissue sarcoma detected through tumor immune microenvironment and genetic profile analyses.
Akane Ariga(Families USA), Kazuhiro Kakimi(Kindai University Hospital), Yuki Funauchi(Japan Association for Development of Community Medicine), Shunji Takahashi(Japanese Foundation For Cancer Research), Yukari Kobayashi(Kindai University), Shingo Sato(Tokyo Institute of Psychiatry), Toshitaka Yoshii(The Orthopaedic Institute), Yasuyoshi Sato(The Cancer Institute Hospital), Keisuke Ae(The Cancer Institute Hospital), Koji Nagaoka(Kyoto University)
Cited by 0
Related Papers
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
|Annals of Oncology|2022|148
Regulation of iron homeostasis by the p53-ISCU pathway
|Scientific Reports|2015|108